Innovative MedTech Rebrands as AnTix Holdings in Strategic Shift to Entertainment Technology

Innovative MedTech, Inc. has completed its planned corporate rebranding and name change to AnTix Holdings, Inc., representing a fundamental shift in the company's strategic direction. This transformation moves the company from its medical technology roots into the growing online ticketing and entertainment technology sector, where it plans to leverage artificial intelligence and Web 3.0 tools to enhance the ticketing and live experience for consumers and partners. The company's ticketing technology has already begun generating revenues, providing what leadership believes will be a strong foundation for future growth.

Michael J. Friedman, President and CEO of AnTix Holdings, Inc., emphasized the strategic importance of this transition, stating that the company aims to build value through innovation, execution and acquisition in a market ripe for significant technological change. The rebranding reflects the company's expansion into artificial intelligence applications for online ticketing, with a mission to bring transparency, efficiency and personalization to the ticketing and entertainment industry. The company remains focused on strengthening its position and appeal to a broad base of investors while increasing shareholder value.

The formal name change process began on September 19, 2025, when the company filed with the State of Delaware a Certificate of Amendment to its Amended and Restated Certificate of Incorporation to change the corporate name from Innovative MedTech, Inc. to AnTix Holdings, Inc. While the common stock currently continues to trade under the ticker symbol IMTH, the company intends to file with FINRA to effectuate the name change and secure a new ticker symbol. Outstanding stock certificates remain valid and do not require exchange at this time due to the name change.

Despite the strategic pivot to entertainment technology, AnTix Holdings maintains its connection to the medical field through its role as exclusive licensor for the Oral Thrush application of Shear Kershman Labs' BioViscid™ bio-adhesive encapsulation. This dual focus positions the company at the intersection of technology innovation across multiple sectors. For additional information about the company's new direction and offerings, visit https://www.antixholdings.com.